IFP Advisors Inc Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

IFP Advisors Inc reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,866 shares of the biotechnology company’s stock after selling 947 shares during the quarter. IFP Advisors Inc’s holdings in Arrowhead Pharmaceuticals were worth $241,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS raised its stake in Arrowhead Pharmaceuticals by 5.2% during the second quarter. KLP Kapitalforvaltning AS now owns 24,300 shares of the biotechnology company’s stock valued at $384,000 after buying an additional 1,200 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Arrowhead Pharmaceuticals by 29.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 1,214 shares during the last quarter. Platinum Investment Management Ltd. boosted its stake in Arrowhead Pharmaceuticals by 12.8% in the 2nd quarter. Platinum Investment Management Ltd. now owns 111,022 shares of the biotechnology company’s stock worth $1,754,000 after purchasing an additional 12,613 shares in the last quarter. Moody Lynn & Lieberson LLC bought a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth about $213,000. Finally, State of Alaska Department of Revenue grew its position in Arrowhead Pharmaceuticals by 7.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 74,819 shares of the biotechnology company’s stock valued at $1,181,000 after purchasing an additional 4,949 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $38.97 on Friday. The firm has a fifty day simple moving average of $28.27 and a two-hundred day simple moving average of $19.56. The firm has a market cap of $5.39 billion, a PE ratio of -30.45 and a beta of 1.13. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $40.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analysts’ expectations of $29.01 million. During the same quarter in the prior year, the business posted ($1.38) EPS. On average, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ARWR shares. Royal Bank Of Canada decreased their target price on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a report on Friday, August 8th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Finally, B. Riley upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.14.

Insider Activity

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the sale, the insider directly owned 212,122 shares in the company, valued at $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 60,000 shares of company stock worth $1,725,000. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.